Clinical Trial Details

USOR 18234

A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer

Purpose/Objective

Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov

Condition: Lung Cancer
Study Type: Interventional
Phase: I
Study Start Date: 04/03/2019
Study Completion Date: 06/2022

This is a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB928 in combination with carboplatin/pemetrexed with or without pembrolizumab and AB122 monotherapy in participants with non-squamous Non-Small Cell Lung Cancer (NSCLC).

 

NCT Number

NCT03846310

Principal Investigator(s)

John Wallmark, MD

Sponsor(s)

Arcus Biosciences, Inc.

Participant Eligibility

• Age: 18 - No Maximum
• Gender: Male, Female